Identification

Generic Name
Riferminogene pecaplasmid
DrugBank Accession Number
DB06394
Background

Riferminogene pecaplasmid (non-viral fibroblast growth factor 1; NV1FGF) is a recombinant DNA plasmid in a pCOR backbone allowing expression of human FGF1.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Fusion proteins
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Non-viral fibroblast growth factor 1
  • NV1FGF
  • Riferminogene pecaplasmid
External IDs
  • XRP0038

Pharmacology

Indication

Investigated for use/treatment in amputation (limb) and peripheral vascular disease.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

NV1FGF is a novel pCOR DNA plasmid–based gene delivery system for local expression of FGF-1. The pCOR plasmid backbone has several features that increase biosafety. These attributes include replication in only a narrow host range of laboratory, but not wild type, Escherichia coli strains, absence of an antibiotic-resistance gene, and lack of the potentially immunostimulatory sequence motifs found in ColE1 plasmids. Preclinical studies of intramuscular administration of NV1FGF have demonstrated that local expression of FGF-1 persists for several weeks. The angiogenic effect of NV1FGF was confirmed in the more severe animal model. The administration of NV1FGF in the hypercholesterolemic hamster model of hindlimb ischemia significantly enhanced the formation of large conductance vessels as well as small resistance arteries in ischemia-injured muscles.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Temusi (Sanofi)

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
3G30P7ME1J
CAS number
1001859-46-6

References

General References
  1. Nikol S, Baumgartner I, Van Belle E, Diehm C, Visona A, Capogrossi MC, Ferreira-Maldent N, Gallino A, Wyatt MG, Wijesinghe LD, Fusari M, Stephan D, Emmerich J, Pompilio G, Vermassen F, Pham E, Grek V, Coleman M, Meyer F: Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther. 2008 May;16(5):972-8. doi: 10.1038/mt.2008.33. Epub 2008 Apr 1. [Article]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentPeripheral Vascular Disease Patient1
2CompletedTreatmentPeripheral Arterial Disease (PAD)1
2CompletedTreatmentPeripheral Arterial Occlusive Disease (PAOD)1
2CompletedTreatmentSevere Peripheral Artery Occlusive Disease1
1CompletedTreatmentPeripheral Arterial Occlusive Disease (PAOD)2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Drug created at March 19, 2008 16:28 / Updated at February 21, 2021 18:52